Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01302834 · OUTCOME

Number of Participants by Work Status Category at 3 Months After End of Treatment

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer · Source last updated 2026-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Three months after end of treatment (6-7 weeks).

What was measured

Participants selected all current work status categories that applied. Therefore, category counts are not mutually exclusive and may sum to more than the number of participants analyzed.

Analysis population: Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had data.

Groups in this outcome

IMRT + Cisplatin

Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin Cisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.

IMRT + Cetuximab

Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab Cetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IMRT + Cisplatin124
IMRT + Cetuximab125

Reported measurements

Currently working in at least one full-time job
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin52Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab46Not reportedNot reportedNot reportedNot reported
Currently working in at least one part-time job
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin12Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab13Not reportedNot reportedNot reportedNot reported
Not employed
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin15Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab16Not reportedNot reportedNot reportedNot reported
Not working outside of the home
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin18Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab21Not reportedNot reportedNot reportedNot reported
On disability
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin20Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab28Not reportedNot reportedNot reportedNot reported
On sick leave
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin12Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab18Not reportedNot reportedNot reportedNot reported
Retired
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin23Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab23Not reportedNot reportedNot reportedNot reported
Student full time
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin0Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab0Not reportedNot reportedNot reportedNot reported
Student part time
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin0Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab0Not reportedNot reportedNot reportedNot reported
Other
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IMRT + Cisplatin5Not reportedNot reportedNot reportedNot reported
IMRT + Cetuximab3Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.5566
    statistical Comment
    Monte Carlo estimation used; categories collapsed for comparison.
    statistical Method
    Fisher Exact
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.5566
    statistical Comment
    Monte Carlo estimation used; categories collapsed for comparison.
    statistical Method
    Fisher Exact
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        52
      2. group Id
        OG001
        value
        46
    title
    Currently working in at least one full-time job
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        13
    title
    Currently working in at least one part-time job
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        15
      2. group Id
        OG001
        value
        16
    title
    Not employed
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        18
      2. group Id
        OG001
        value
        21
    title
    Not working outside of the home
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        20
      2. group Id
        OG001
        value
        28
    title
    On disability
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        18
    title
    On sick leave
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        23
      2. group Id
        OG001
        value
        23
    title
    Retired
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Student full time
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Student part time
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        3
    title
    Other
denoms
  1. counts
    1. group Id
      OG000
      value
      124
    2. group Id
      OG001
      value
      125
    units
    Participants
description
Participants selected all current work status categories that applied. Therefore, category counts are not mutually exclusive and may sum to more than the number of participants analyzed.
groups
  1. description
    Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin Cisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
    id
    OG000
    title
    IMRT + Cisplatin
  2. description
    Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab Cetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks IMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
    id
    OG001
    title
    IMRT + Cetuximab
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible participants enrolled to the quality of life (QOL) substudy who received protocol treatment and had data.
reporting Status
POSTED
time Frame
Three months after end of treatment (6-7 weeks).
title
Number of Participants by Work Status Category at 3 Months After End of Treatment
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice